Background Nivolumab combined with ipilimumab resulted in longer progression-free survival
and a higher objective response rate than ipilimumab alone in a phase 3 trial involving …

Background In the phase 1–2 portion of an adaptive trial, REGEN-COV, a combination of the
monoclonal antibodies casirivimab and imdevimab, reduced the viral load and number of …

Background Recent data suggest that complications and death from coronavirus disease
2019 (Covid-19) may be related to high viral loads. Methods In this ongoing, double-blind, …

Background More than half of patients with polymyalgia rheumatica have a relapse during
tapering of glucocorticoid therapy. Previous studies have suggested that interleukin-6 …

Purpose Approximately 40% of patients with advanced melanoma who received nivolumab
combined with ipilimumab in clinical trials discontinued treatment because of adverse events …

BACKGROUND: The Melasma Area and Severity Index (MASI), the most commonly used
outcome measure for melasma, has not been validated. OBJECTIVE: We sought to determine …

BACKGROUND: The trends in hospitalization rates and risk factors for severe bronchiolitis
have not been recently described, especially after the routine implementation of prophylaxis …

Patients with hepatitis C virus (HCV) genotype 3 infection, especially those with advanced
liver disease, are a challenging population in urgent need of optimally effective therapies. The …

Purpose The addition of nivolumab (anti–programmed death-1 antibody) to ipilimumab (anti–cytotoxic
T-cell lymphocyte–associated 4 antibody) in patients with advanced melanoma …

Purpose The clinical activity observed in a phase I dose-escalation study of concurrent
therapy with nivolumab (NIVO) and ipilimumab (IPI) in patients with previously treated or …